100 research outputs found
Proyecto de plantación de 8,35 ha de viñedo en regadío en la localidad de Nava del Rey (Valladolid)
Resumen no disponibleGrado en Ingeniería Agrícola y del Medio Rura
COVID in Pediatric Age: an opinion paper.
The incidence of COVID in pediatrics was underestimated during the first months of the pandemic due to the oligosymptomatic nature of the infection in many children and the scarcity of diagnostic tests applied to this population. It is now accepted that children are infected and transmit the disease in the same way as adults. On the contrary, children have less severe and less lethal COVID, probably due to a lower maturity of the child’s immune system, a lower number of ACE2 receptors and the lower presence of comorbidities in this population group.
The development of a multisystemic inflammatory syndrome after SARS-CoV-2 infection in children, despite its rarity, is a very serious condition that frequently requires intensive care. Other less severe post-COVID manifestations have been described in children but are not yet well defined.
COVID has had and continues to have a significant psychological impact on the children themselves, on their caregivers and on the exacerbation of pre-existing psychiatric conditions. We apply adult therapeutic principles to children but with very low levels of evidence. Information on the tolerability of the available medications in this population group is still scarce. The mortality of COVID in children is very low and generally affects children with significant comorbidities.
There are, at present, three vaccines licensed for pediatric use which are compatible with all other vaccines applicable to children.
In these circumstances, there has been much speculation about the indication for vaccination in the pediatric age group, but given its good tolerance, there are clinical and ethical reasons that, in our opinion, justify it.post-print189 K
El papel del varón en la conciliación: aspectos educativos
El Seminario Permanente sobre conciliación de la vida laboral, personal y familiar del Instituto de Ciencias para la Familia ha sido creado como espacio interdisciplinar de reflexión e intercambio de ideas sobre cuestiones relacionadas con la conciliación. Esta publicación recoge las sesiones dedicadas a las familias con dos sueldos y tres trabajos
Expansion of serotype coverage in the universal pediatric vaccination calendar: Short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain
In Madrid, Spain, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in the pediatric universal vaccination
calendar in June 2010. A prospective clinical surveillance that included all children hospitalized with culture- and/or PCR-confirmed
invasive pneumococcal disease (IPD) was performed in all Madrid hospitals. The incidence rates (IRs) (defined as the
number of cases/100,000 inhabitants aged<15 years) in the PCV7 (May 2007 to April 2010) versus PCV13 (May 2011 to April
2012) periods were compared. There were 499 cases in the PCV7 period and 79 cases in the PCV13 period. Globally, the IR significantly
decreased from 17.09 (PCV7 period) to 7.70 (PCV13 period), with significant decreases (PCV7 versus PCV13 periods) in
all age groups for bacteremic pneumonia (5.51 versus 1.56), parapneumonic pneumococcal empyema (PPE) (5.72 versus 3.12),
and meningitis (2.16 versus 0.97). In the PCV13 period, significant reductions (the IR in the PCV7 period versus the IR in the
PCV13 period) were found in IPDs caused by PCV13 serotypes (13.49 versus 4.38), and specifically by serotypes 1 (globally [4.79
versus 2.53], for bacteremic pneumonia [2.23 versus 0.97], and for PPE [2.26 versus 1.17]), serotype 5 (globally [1.88 versus 0.00],
for bacteremic pneumonia [0.89 versus 0.00], and for PPE [0.55 versus 0.00]), and serotype 19A (globally [3.77 versus 0.49], for
bacteremic pneumonia [0.72 versus 0.00], for PPE [0.89 versus 0.00], and for meningitis [0.62 versus 0.00]). IPDs caused by non-
PCV13 serotypes did not increase (IR, 3.60 in the PCV7 period versus 3.31 in the PCV13 period), regardless of age or presentation.
No IPDs caused by the PCV13 serotypes were found in children who received 3 doses of PCV13. The number of hospitalization
days and sanitary costs were significantly lower in the PCV13 period. The switch from PCV7 to PCV13 in the universal
pediatric vaccination calendar provided sanitary and economical benefits without a replacement by non-PCV13 serotypesThis work was supported in part by an unrestricted grant from Pfizer
S.L.U., Madrid, Spain.
J.P. and J.R.-C. have received travel fees from Pfizer for attending
and/or speaking at symposiums and congresses. C.M. is an employee of
Pfizer S.L.U., Madrid, Spain
- …